HomeNewsDrug Discovery & Development

Boehringer Ingelheim and CBmed Forge Partnership to Advance Cancer Treatment Development

Boehringer Ingelheim and CBmed Forge Partnership to Advance Cancer Treatment Development

Boehringer Ingelheim and CBmed GmbH Center for Biomarker Research in Medicine (CBmed) have announced a significant long-term strategic collaboration aimed at accelerating the development of groundbreaking medicines for cancer treatment.

The partnership, unveiled with great anticipation, will harness translational medicine approaches to drive the advancement of first-in-class therapies, ultimately aiming to revolutionize the lives of individuals battling cancer.

Despite the remarkable progress of precision medicine in cancer care, a staggering 97 out of every 100 clinical trials investigating compounds for specific indications fail to deliver significant benefits for patients. This often stems from a limited understanding of how cancer treatments target cancer cells or activate the immune system, as well as uncertainty regarding which patients could benefit from particular therapies. Translational medicine offers a solution by identifying biomarkers to assess treatment efficacy and deepening our understanding of disease pathology.

Vittoria Zinzalla, Global Head of Oncology Translational Medicine and Clinical Pharmacology at Boehringer Ingelheim, expressed enthusiasm about the collaboration, stating, "We are thrilled to unite with CBmed's team of translational science experts. This strategic partnership will bolster our endeavors to enhance the success rate of clinical development by translating research breakthroughs into actionable insights for clinical application. It will also enable us to broaden our pipeline and fulfill our mission of transforming the lives of individuals affected by cancer."

Thomas Pieber, Chief Scientific Officer of CBmed, echoed Zinzalla's sentiments, highlighting the partnership's potential to support multiple projects across Boehringer Ingelheim's oncology pipeline. Pieber emphasized CBmed's commitment to delivering tailored therapies that revolutionize patient care.

As part of the collaboration, CBmed will expand its research infrastructure in Graz, Austria, with dedicated laboratories and offices, accommodating up to 30 experienced translational scientists and physicians. Robert Lobnig, Chief Executive Officer of CBmed, outlined the expansion plan, underscoring the company's dedication to fostering innovation and driving impactful research outcomes.

The collaboration has garnered support from prominent figures in the Austrian medical community. Hellmut Samonigg, Rector of the Medical University of Graz, and Markus Müller, Rector of the Medical University of Vienna, both hailed the partnership as a testament to the region's growing prominence in biomedical research.

CBmed, renowned for its pioneering work in translational medicine research, bridges the gap between scientific discoveries and patient care through close collaboration with the Medical Universities of Graz and Vienna. The company's cutting-edge multi-omics technology platform, coupled with access to extensive biobanks, positions it as a leader in biomarker discovery.

By leveraging CBmed's expertise, Boehringer Ingelheim aims to identify and validate biomarkers across its oncology portfolio, facilitating early proof of therapeutic effect, identification of new indications, and patient selection.

Read more on:
More news about: drug discovery & development | Published by Manvi | February - 12 - 2024

Last news about this category



We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members